What is the recommended dose of sodium polystyrene sulfonate (Kayexalate) for treating hyperkalemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The recommended dose of sodium polystyrene sulfonate (Kayexalate) for treating hyperkalemia is typically 15 g 1-4 times daily as needed, administered orally or rectally, with caution due to potential serious gastrointestinal adverse events. When considering the treatment of hyperkalemia, it's crucial to weigh the benefits and risks of sodium polystyrene sulfonate (SPS) against other potassium-binding agents. According to the most recent evidence from 1, SPS has a variable onset of action, and its use is associated with significant adverse events, including intestinal ischemia and colonic necrosis. Key considerations for the use of SPS include:

  • Dosing: 15 g 1-4 times daily as needed, orally or rectally, as indicated in 1.
  • Administration: Oral administration typically involves mixing the powder with water or a sweetened liquid, while rectal administration is given as a retention enema.
  • Monitoring: Serum potassium levels should be monitored every 6 hours during therapy to adjust the treatment duration accordingly.
  • Side effects: Common side effects include constipation, which may be mitigated by co-administration with sorbitol, as well as hypomagnesemia, hypokalemia, and hypocalcemia.
  • Safety concerns: SPS has been linked to serious gastrointestinal adverse events, making newer potassium binders like patiromer or sodium zirconium cyclosilicate potentially preferred alternatives due to their improved safety profiles, as noted in 1. Given the potential risks and the availability of alternative treatments with better safety profiles, the decision to use SPS should be made cautiously and with careful consideration of the individual patient's needs and risk factors.

From the FDA Drug Label

The average total daily adult dose of Sodium Polystyrene Sulfonate is 15 g to 60 g, administered as a 15 g dose (four level teaspoons), one to four times daily. The average adult dose is 30 g to 50 g every six hours for rectal administration.

The recommended dose of sodium polystyrene sulfonate (Kayexalate) for treating hyperkalemia is:

  • Oral: 15 g to 60 g per day, given as 15 g (four level teaspoons) one to four times daily.
  • Rectal: 30 g to 50 g every six hours. 2 2

From the Research

Sodium Polystyrene Sulfonate Dosing for Hyperkalemia

  • The recommended dose of sodium polystyrene sulfonate (SPS) for treating hyperkalemia is not universally established, but studies suggest the following:
    • A single 60-g oral dose of SPS can effectively treat mild hyperkalemia with minimal risk of hypokalemia 3
    • Lower doses, such as 15-g oral doses, may not be as effective in reducing serum potassium levels 3, 4
    • Higher doses, such as 30-g oral doses, may be more effective, but the difference in efficacy compared to lower doses is not always statistically significant 3, 4
  • The effectiveness of SPS in reducing serum potassium levels can vary depending on the patient population and the severity of hyperkalemia:
    • In patients with chronic kidney disease (CKD), SPS has been shown to be effective in reducing serum potassium levels over a period of 7 days 5
    • In patients with mild hyperkalemia, SPS may not have a clinically significant effect on reducing serum potassium levels 4
  • It is essential to note that SPS is not always the most effective treatment for hyperkalemia, and other treatments, such as patiromer, may be more effective in certain situations 6
  • The use of SPS can be associated with adverse effects, such as gastrointestinal side effects, and its use should be carefully considered in each patient 6, 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.